IMMU Immunomedics Inc.

0  0%
Previous Close 13.24
Price To Book 13.94
Market Cap 2,535,953,971
Shares 191,537,309
Volume 0
Short Ratio
Av. Daily Volume 2,911,149

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated.
Castration-resistant prostate cancer (CRPC)
Phase 1/2 data February 11, 2019 noted ORR 31% (14/45), with 2 CRs and 12 PRs. Presentation ASCO-GU February 15, 2019.
Urothelial cancer
CRL issued January 17, 2019. NDA to be refiled early 4Q 2019.
Cancer - metastatic triple-negative breast cancer
Phase 2 update provided at ASCO June 2016. Ongoing through 2017.
Non-small cell lung cancer (NSCLC)
Phase 2 interim data presented April 2016
Labetuzumab govitecan
Metastatic colorectal cancer (mCRC)
Phase 3 trial terminated due to poor efficacy
Clivatuzumab tetraxetan
Cancer - Pancreatic
Endpoints not met July 2015
Epratuzumab (EMBODY 1 and 2)
Phase 3 trial has been initiated.
HR+/HER2- metastatic breast cancer
Phase 1/2 interim analysis 3Q 2019.
Urothelial cancer

Latest News

  1. Notable Insider Buys This Past Week: American Airlines, MGM and More
  2. Immunomedics to Participate in Upcoming Healthcare Conferences
  3. 2 Biotech Names See Directors Direct Cash to Their Shares
  4. Edited Transcript of IMMU earnings conference call or presentation 9-May-19 12:00pm GMT
  5. Immunomedics: 1Q Earnings Snapshot
  6. Immunomedics Reports First Quarter 2019 Results and Provides Corporate Update
  7. Immunomedics To Participate In Upcoming Healthcare Conferences
  8. Immunomedics to Report First Quarter 2019 Results and Host Conference Call and Webcast on May 9, 2019
  9. Stocks making the biggest moves midday: Disney, Restaurant Brands, Gardner Denver, Target & more
  10. Immunomedics and Everest Medicines Announce Exclusive License Agreement for Sacituzumab Govitecan in East and Southeast Asia Excluding Japan
  11. Immunomedics Announces Departure of Chief Medical Officer
  12. Seattle Genetics (SGEN) Q1 Loss Narrows, Revenues Top Mark
  13. Is Immunomedics, Inc. (IMMU) A Good Stock To Buy?
  14. Is Immunomedics, Inc. (NASDAQ:IMMU) Trading At A 34% Discount?
  15. Immunomedics Announces Promotion Agreement With Janssen for Erdafitinib in the U.S.
  16. Why Analysts Reduced Target Price of Immunomedics
  17. Immunomedics Appoints Barbara G. Duncan to Board of Directors
  18. Immunomedics to Participate in Cowen and Company 39th Annual Health Care Conference
  19. Research Report Identifies Axalta Coating, The Home Depot, Immunomedics, Kosmos Energy, Casa, and Ormat Technologies with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
  20. Edited Transcript of IMMU earnings conference call or presentation 25-Feb-19 10:00pm GMT